Skip to main content
Advertisement
Advertisement
INSM
INSM logo
Insmed, Inc.
144.46
USD
Sponsored
+24.66
+20.58%
Nov 19, 15:59 UTC -5
Closed
exchange

After-Market

143.90

-0.56
-0.39%

Insmed, Inc. (INSM) Earnings

INSM Earnings Reports

Positive Surprise Ratio

INSM beat 17 of 44 last estimates.

39%

Next Report

Date of Next Report
Feb 17, 2027
Estimate for Q4 26 (Revenue/ EPS)
$606.07M
/
-$0.29
Implied change from Q3 26 (Revenue/ EPS)
+15.57%
/
-36.96%
Implied change from Q4 25 (Revenue/ EPS)
+129.71%
/
-81.17%

Insmed, Inc. earnings per share and revenue

On Oct 29, 2026, INSM reported earnings of -0.46 USD per share (EPS) for Q3 26, missing the estimate of -0.38 USD, resulting in a -19.08% surprise. Revenue reached 524.43 million, compared to an expected 511.38 million, with a 2.55% difference. The market reacted with a +15.06% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 8 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 606.07 million USD, implying an decrease of -36.96% EPS, and increase of 15.57% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Invivyd, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+26.47%
logo
Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%
logo
Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q1 27
Estimate
-$0.26
Actual
-$0.20
Surprise
+23.61%
logo
Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%
logo
Lantern Pharma Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.81
Surprise
-126.89%
logo
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
logo
Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-
Actual
-$0.34
Surprise
-
FAQ
For Q3 2026, Insmed, Inc. reported EPS of -$0.46, missing estimates by -19.08%, and revenue of $524.43M, 2.55% above expectations.
The stock price moved up 15.06%, changed from $96.98 before the earnings release to $111.59 the day after.
The next earning report is scheduled for Feb 17, 2027.
Based on 8 analysts, Insmed, Inc. is expected to report EPS of -$0.29 and revenue of $606.07M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement